Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a five ...

Coherus has agreed to sell its biosimilar Udenyca—which references Amgen’s febrile neutropenia drug Neulasta—to Intas Pharmaceuticals for up to $558.4 million. The deal, which is expected to ...

Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a ...

Indian drugmaker Intas Pharmaceuticals is reportedly readying a bid for Biogen’s (NASDAQ:BIIB) biosimilars business that could value the unit at up to $1B. Intas has already submitted a non ...

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state investment firm Temasek and Abu Dhabi Investment Authority (ADIA) as its investors, ...

Ahmedabad: Intas Pharmaceuticals Ltd has announced a strategic exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma ...

Intas Pharmaceuticals Limited has informed that its manufacturing facility SEZ (Pharmez) near Ahmedabad has been listed under ‘Import Alert’ by the US Food and Drug Administration (USFDA).

Ahmedabad-based Intas Pharmaceuticals on Wednesday acquired Spanish drug maker Combino Pharm's hospital business in Spain and Portugal for an undisclosed amount. The acquisition will help Intas ...

to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million.